AlgiPharma Phase I clinical trial shows excellent safety and tolerability data for respiratory diseases

OligoG CF-5/20 was well tolerated when administered by inhalation to 28 healthy subjects. All adverse events monitored were mild and transient. No serious adverse events, no deaths, no discontinuations.

Read more

For more information contact:
Yngvar P. Berg, CEO;
Astrid Hilde Myrset, Clinical Director;

January 2010